Education
About Us
Working with TipRanks
Follow Us
Neumora Therapeutics, Inc. (NMRA)
NASDAQ:NMRA
Earnings Data
Report Date
May 13, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.38Last Year’s EPS
-0.34Same Quarter Last Year
Moderate Buy
Based on 8 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 03, 2025
|% Change Since: -27.56%
|Next Earnings Date:May 13, 2025
Earnings Call Sentiment|Neutral
The earnings call reflects a company in transition, with strong financials and leadership changes poised to drive future growth. However, setbacks in the KOASTAL-1 study and the discontinuation of bipolar depression trials pose significant challenges. The overall sentiment is balanced between optimism for future potential and caution due to current setbacks.Company Guidance
In the call, Neumora Therapeutics provided detailed guidance on their ongoing and future clinical programs, emphasizing their strategic focus on addressing brain diseases. They reported advancements in their pipeline, including seven programs targeting novel mechanisms. Notably, they are optimizing their Phase 3 KOASTAL-2 and KOASTAL-3 studies for navacaprant in major depressive disorder (MDD) after the KOASTAL-1 study did not meet its endpoints. They have tested navacaprant in nearly 600 patients and plan to report top-line data for KOASTAL-3 in Q1 2026 and KOASTAL-2 in Q2 2026. Additionally, they discontinued navacaprant's Phase 2 trial for bipolar depression to focus resources on MDD. Neumora is also advancing NMRA-511 in a Phase 1b study for Alzheimer's agitation, with data expected by year-end. Financially, they ended 2024 with $307.6 million in cash, projecting operations support into mid-2026. Total operating expenses for 2024 were $243.8 million, primarily driven by their Phase 3 programs and business growth investments.Strong Financial Position
Neumora ended 2024 with $307.6 million in cash, cash equivalents, and marketable securities, expected to support operations into mid-2026.
Pipeline Progress
Neumora has an industry-leading pipeline with seven programs targeting novel mechanisms of action, including the advancement of NMRA-511 in a Phase 1b study for Alzheimer's agitation and plans to progress the M4 franchise by mid-2025.
New Leadership Roles
Paul Berns has taken over as CEO and Josh Pinto has been appointed President, reflecting a strategic leadership restructuring.
---
NMRA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
NMRA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 03, 2025 | $1.56 | $1.40 | -10.26% |
| Nov 12, 2024 | $13.64 | $11.31 | -17.08% |
| Aug 06, 2024 | $11.96 | $11.99 | +0.25% |
| May 07, 2024 | $9.35 | $9.81 | +4.92% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Neumora Therapeutics, Inc. (NMRA) report earnings?
Neumora Therapeutics, Inc. (NMRA) is schdueled to report earning on May 13, 2025, TBA Not Confirmed.
What is Neumora Therapeutics, Inc. (NMRA) earnings time?
Neumora Therapeutics, Inc. (NMRA) earnings time is at May 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NMRA EPS forecast?
NMRA EPS forecast for the fiscal quarter 2025 (Q1) is -0.38.
---